Space Pharmacology: Medical Kits, Medication Use and Drug Stability
Also: ISS medical kit · drug stability in space · medication expiry spaceflight · sleep medication astronauts
RadiationDistance from EarthHostile/Closed EnvironmentPharmacologyBehavioral Health & SleepPreflight & TrainingIn-flightLEO short-durationLEO long-durationCislunar / Lunar orbitLunar surfaceMars transit & surfaceClinicianOperator / SFPResearcher
- Medication use in space is broadly similar to ambulatory medicine on Earth, except sleep aids — used about 10 times more often during ISS missions (71% of crew reported use). ◆◆◆◇ Moderate · F
- In low Earth orbit, crews have not been affected by loss of drug effectiveness from stability or radiation; most drugs perform as expected and are restocked before expiry. ◆◆◆◇ Moderate · F E
- Drugs do degrade faster in space: in one 28-month study, more flight than ground formulations failed potency limits, and failures rose with time; a 550-day sample found 8 of 9 drugs within USP limits. ◆◆◇◇ Low · F
- For Mars-class missions (1–5 years, no resupply), typical 1–2-year expiry dates, radiation and limited volume are unsolved problems. ◆◆◆◇ Moderate · E M
- Pharmacokinetics may be altered (fluid shifts, gut motility, liver blood flow), but in-flight PK/PD data are scarce — dose as on Earth and monitor response. ◆◆◇◇ Low · E F
Proposed certainty (◆ High → ◇ Very low) and evidence-type tags: F flight · A analog · M model/animal · C computational · E expert/operational/standards. Grades are AI-proposed and pending medical reviewer confirmation. How we grade.
What to do
Preflight medication review (any prescriber)
- Reconcile all medications and supplements, including OTC. Crew can take some OTC drugs without discussing them with the flight surgeon, and historically this was poorly documented [1].
- Trial new drugs on the ground before flight — side effects should be known before launch.
- Flag: sedatives and hypnotics (combined use with in-flight sleep aids), anticholinergics (urinary retention, heat intolerance), QT-prolonging drugs, anticoagulants (trauma at landing), estrogen-containing drugs (VTE), drugs with narrow therapeutic index.
- Supply and stability: the patient needs enough for the mission plus contingency; ask the operator about storage conditions and repackaging (both can affect stability) [3].
Sleep medicines — a practical flag
Sleep aids were the most frequently used drug class on ISS: 71% of crewmembers reported use, about 10 times the rate in ambulatory medicine on Earth [1][2]. Much medication use was driven by operations — schedule shifts, lighting, EVAs and exercise — so fixing schedules and light exposure may reduce need [2]. After landing, review whether a sleep aid started in flight should be tapered.
Red flags
- Apparent treatment failure: on ISS, the recorded treatment failures were mostly skin rash [1][2]. Reconsider the diagnosis: fluid-shift “congestion” does not respond to decongestants [1].
- Expired or discolored medication on long missions — check for physical changes (discoloration, phase separation) [3].
Overview: what astronauts take
| Class | % of ISS crew reporting use | Reported efficacy |
|---|---|---|
| Sleep aids | 71 | Somewhat–very effective |
| Congestion/allergy | 55 | Somewhat–very effective |
| Headache | 54 | Somewhat–very effective |
| Joint pain | 46 | Somewhat–very effective |
| Back / muscle pain | 21 / 21 | Somewhat–very effective |
| Alertness aids | 21 | Very effective |
| Rash treatments | 25 | Ineffective (2 reports) |
NASA OCHMO brief summarizing Wotring 2015 (24 crewmembers, 20 missions over 30 days) [1][2].
Shuttle-era data (summarized by NASA): 94% of crewmembers used medications; 85% of doses had no side effects and 80% were perceived as effective, with ineffectiveness reported most on the first mission day [1]. Better tracking (the Dose Tracker app) found far more medication use than earlier records — about four medications per crewmember per week — attributed to better reporting rather than more use [1].
Does storage in space degrade drugs?
| Study | Design | Finding |
|---|---|---|
| Du et al. 2011 [3] | 35 formulations, identical kits on ISS and on the ground, up to 28 months | More flight than ground formulations failed USP potency criteria (at 28 months, 9 flight vs 17 ground formulations still met them); failures rose with time in space independent of expiry; degradation faster in space for many; most solid forms met dissolution standards; radiation dose higher in flight while temperature/humidity were similar |
| Wotring 2016 [4] | 9 medications returned after ~550 days on ISS, one time point, no ground controls | 8 of 9 within USP limits; melatonin (11 months past expiry) failed; no unusual degradation products |
NASA’s summary: most medications lost less than 20% of active ingredient in the 2011 study, and in LEO there has been no effect on crew from lack of medication effectiveness [1]. Repackaging solid dosage forms into flight dispensers and chronic low-dose radiation are suspected contributors [3]. Ground radiation tests at NASA’s Space Radiation Laboratory found only small changes, mostly within acceptable limits [1][5].
Altered pharmacokinetics
Spaceflight may change absorption (gastric emptying, gut transit, motion sickness), distribution (fluid shifts, plasma proteins), hepatic metabolism and renal clearance [1][6]. Few in-flight PK data exist and systematic PK/PD studies are lacking; bed rest is used as a surrogate [6].
Mission-type differences
| Mission | Pharmacy approach |
|---|---|
| LEO short / commercial | Personal kit plus vehicle kit; return to Earth possible within hours to days |
| LEO long (ISS) | Formulary kept limited because evacuation is an option; regular resupply before expiry [1][7] |
| Lunar | Days from Earth; broader kit needed for stabilization until return |
| Mars | 1–5-year missions exceed typical 1–2-year expiry; no resupply; higher radiation; volume and mass limits [1][5]. A NASA analysis found only 16% of the 107 medications then in the ISS formulary would last 2.5 years by expiration date once ordering and packing times were included [9] |
Terrestrial parallels
- Shelf-life extension: the U.S. federal Shelf-Life Extension Program (SLEP) shows many stockpiled drugs remain potent years past labeled expiry under proper storage [1] — relevant to remote, military and disaster medicine.
- Remote and expedition medicine (Antarctica, ships, wilderness): fixed formularies chosen by probability of need and severity.
- Polar/shift-work sleep medicine: high hypnotic use under disrupted light and schedules.
Gaps
- Stability of drugs beyond expiry and under deep-space radiation [1][5].
- In-flight PK/PD for most drugs [6].
- Optimal formulary and on-demand manufacturing for exploration missions [5][7].
Deeper dive: expiry vs shelf life
NASA’s brief notes neither the expiration date nor shelf life means a drug becomes harmful afterwards; one drug (tetracycline) has been associated — not strongly proven — with renal toxicity (Fanconi syndrome) when used past expiry [1]. Federal SLEP testing since 1986 has supported extending many products’ usable life [1]. For exploration missions NASA is examining evidence-based shelf-life extension; Wotring’s 550-day sample showed several drugs still within USP limits 5–8 months past expiry [4].
Commercial spaceflight notes
Commercial operators set their own formularies. Ask participants to bring a list of what they will carry and when, and check for interactions with their usual medications. Antiemetics and sleep aids are the drugs most likely to be used.
Clinical pearls
- “Is this a drug problem or a fluid-shift problem?” — stuffy nose and headache in early flight are often fluid shift, not infection [1].
- Ask returning crew what they took in flight; sleep aid use is common and may need a plan after landing.
Evidence profile
- Overall certainty
- ◆◆◇◇ Low (proposed)
- Evidence types
- F · Flight dataE · Expert / operational / standardsM · Model / animal
- Literature through
- 2026-10-14
NASA-STD-3001 requirements referenced 4
| Requirement | Title | Plain-language meaning |
|---|---|---|
| [V1 3004] | In-Mission Medical Care | Includes medical kits (personal and vehicle) and resources to diagnose and treat expected conditions. |
| [V2 7043] | Medical Capability | Vehicle must provide medical capability (equipment, consumables, medications) per the mission's medical concept. |
| [V2 7045] | Medical Equipment Usability | Medical equipment must be usable by non-physician crew. |
| [V2 7115] | Medical Treatment, Personal Supplies, and Impacts to Environmental Systems | Medical items are evaluated for vehicle impacts (e.g., off-gassing, flammability). |
IDs as published in NASA-STD-3001 Vol. 1 Rev C (2023-09-15) and NASA-STD-3001 Vol. 2 Rev F (2026-07-14). NASA-STD-3001 binds NASA programs; it is not a regulation for commercial flights. Paraphrased; read the standard for exact wording. Standards quick reference.
References 9
- NASA OCHMO. Pharmaceutical Care. Medical Technical Brief OCHMO-MTB-012, Revision B (2026) (file published as ochmo-tb-006-pharmaceuticals.pdf). www.nasa.gov/wp-content/uploads/2023/12/ochmo-tb-006-pharmac… NASA E
- Wotring VE. Medication use by U.S. crewmembers on the International Space Station. FASEB J. 2015;29(11):4417-4423. doi:10.1096/fj.14-264838 PMID:26187345 Peer-reviewed F
- Du B, Daniels VR, Vaksman Z, Boyd JL, Crady C, Putcha L. Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. AAPS J. 2011;13(2):299-308. doi:10.1208/s12248-011-9270-0 PMID:21479701 Peer-reviewed F
- Wotring VE. Chemical potency and degradation products of medications stored over 550 Earth days at the International Space Station. AAPS J. 2016;18(1):210-216. doi:10.1208/s12248-015-9834-5 PMID:26546565 Peer-reviewed F
- Blue RS, Chancellor JC, Antonsen EL, et al. Limitations in predicting radiation-induced pharmaceutical instability during long-duration spaceflight. NPJ Microgravity. 2019;5:15. doi:10.1038/s41526-019-0076-1 PMID:31231677 Peer-reviewed E
- Kast J, Yu Y, Seubert CN, Wotring VE, Derendorf H. Drugs in space: pharmacokinetics and pharmacodynamics in astronauts. Eur J Pharm Sci. 2017;109S:S2-S8. doi:10.1016/j.ejps.2017.05.025 PMID:28533143 Peer-reviewed E
- NASA Human Research Program. Evidence Report: Risk of Ineffective or Toxic Medications During Long-Duration Exploration Spaceflight (2023). humanresearchroadmap.nasa.gov/evidence/other/Pharm%20evidenc… NASA E
- NASA OCHMO. NASA-STD-3001, Volume 2, Revision F (2026). standards.nasa.gov/standard/NASA/NASA-STD-3001_VOL_2 Standard E
- NASA Human Research Program. Evidence Report: Risk of Adverse Health Outcomes and Decrements in Performance due to In-Flight Medical Conditions (2017). humanresearchroadmap.nasa.gov/evidence/reports/Medical.pdf NASA E
Links and DOI metadata were machine-checked on 2026-10-14 (URL resolves; DOI title/journal/year matched via Crossref). Human verification of each cited claim against its source is still required before review. NASA documents are U.S. Government works (public domain) and are summarized with attribution; journal articles are summarized, not reproduced.
Article info
- Authors
- Pending (AI-assisted draft)
- Reviewer
- Pending review
- Last reviewed
- Pending review
- Literature through
- 2026-10-14
- AI-assisted
- Yes (disclosed)
- COI
- Pending
- License
- CC BY-SA 4.0
- Use
- Educational only · Disclaimer
- Cite this version
- Pending first edition